GSK-Hansoh's ADC deal surprised many people.But if future clinical data fail to meet expectation,GSK could return the product to Hansoh.Current valuation isn't cheap.A drop below HK$10 is a better buy
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.